Why the study?
Low blood pressure limits GDMT up-titration and predicts poor outcomes in heart failure, prompting assessment of ABPM's value in detecting low BP and its impact on GDMT optimization and prognosis.
Does ambulatory blood pressure monitoring to detect sustained or masked low systolic blood pressure predict GDMT intolerance and adverse outcomes in patients with heart failure?
Does ambulatory blood pressure monitoring to detect sustained or masked low systolic blood pressure predict GDMT intolerance and adverse outcomes in patients with heart failure?
Masked low systolic blood pressure identified by ambulatory monitoring is common in heart failure patients and is associated with a lower likelihood of achieving GDMT target doses and higher rates of mortality and rehospitalization.
Masked low SBP on ambulatory monitoring identifies higher-risk HF patients; leaves open whether ABPM-guided GDMT optimization improves outcomes.
BACKGROUND: Low blood pressure (BP) limits the up-titration of guideline-directed medical therapies (GDMTs) and predicts poor outcomes in heart failure (HF). We assessed the value of ambulatory BP monitoring (ABPM) in detecting low BP and its impact on GDMTs optimization and prognosis in HF. METHODS: In 491 HF patients initiating GDMTs from the Risk Evaluation and Management in Heart Failure (REM-HF) study since April 2018 to December 2022, ABPM was measured in addition to office BP. Participants were classified as sustained low systolic BP (SBP) (24-hour and office SBP < 120 mmHg), masked low SBP (24-hour SBP < 120 mmHg, office SBP ≥ 120 mmHg), and no low SBP. The primary outcome was a composite of all-cause mortality and HF rehospitalization. GDMTs target dose achievement was assessed at 3 months. Logistic regression and Cox regression models were used to assess GDMTs optimization and outcomes across SBP groups. RESULTS: Sustained, masked, and no low SBP were observed in 25.3%, 30.8%, and 44.0% of patients, respectively. Both sustained (OR 2.36, 95%CI 1.25-4.47) and masked low SBP (OR 2.32, 95%CI 1.11-4.87) groups were associated with lower likelihood of achieving GDMTs target doses. Over a median 21-month follow-up, all-cause mortality and HF rehospitalization rates were higher in sustained (HR 2.45, 95% CI 1.56-3.86) and masked low SBP (HR 1.68, 95% CI 1.08-2.62) groups. No difference was found in the target dose achievement and outcomes between the two low SBP groups. CONCLUSION: Sustained and masked low SBP were common in HF and both associated with GDMTs intolerance and adverse outcomes.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: